Health insurance stocks: UnitedHealth Group, CVS, and Humana are rising on Medicare Advantage news
Health insurance stocks, including those of UnitedHealth Group, Humana, and CVS Health, are increasing after the Trump administration decided to significantly raise Medicare insurer payments. This decision backtracks on an earlier, lower increase proposal and follows extensive lobbying from the private insurance industry. The revised plan means an additional $13 billion will be paid to private health insurers for Medicare Advantage in 2027, with a net average increase of 2.48%.
New Medicare Payment Rate Released. Why UnitedHealth Stock Is Popping.
The federal government announced an average increase of 2.48% in Medicare payments to insurers for the next year. This highly anticipated financial news is significant for major health insurance companies, particularly UnitedHealth and Humana. Medicare Advantage, which covers 35 million beneficiaries, is a crucial part of these insurers' businesses.
S&P 500 Futures Decline in Premarket Trading; Valmont Industries, Loews Lag
S&P 500 futures are declining in premarket trading, with specific companies like Valmont Industries and Loews lagging. Conversely, Humana Inc. (HUM) and Brookfield Wealth Solutions Ltd. (BNT) are showing significant gains, up 9.8% and 9.7% respectively, as the U.S. stock markets approach their open. This article provides an early look at market movements before trading begins.
Broadcom, United Health, Humana, Amazon, Universal Music, and More Stock Market Movers
The article highlights several major companies, including Broadcom, United Health, Humana, Amazon, and Universal Music, as today's stock market movers. Stock futures were reportedly rising on Tuesday as investors anticipated President Donald Trump's deadline for Iran to agree to a peace deal.
CMS Medicare Rate Decision Reframes UnitedHealth Group Valuation And Risk Profile
The CMS has finalized a 2.48% rate increase for 2027 Medicare Advantage and Part D payments, which is higher than initially expected and provides clarity for UnitedHealth Group, a major Medicare Advantage operator. This decision offers a more supportive baseline for Medicare Advantage profitability, despite ongoing questions about medical costs and competitive pressures. While the company's shares are considered undervalued by Simply Wall St, a flagged risk is UnitedHealth Group's high debt level.
Centene Corp. stock: Why it's drawing investor attention amid healthcare shifts
Centene Corp. is gaining investor attention due to a 4% stock increase following a rise in Medicare Advantage rates for 2027, signaling brighter prospects for the managed care giant. The article details Centene's business model focused on government-funded healthcare programs like Medicaid and Medicare, its competitive advantages in a fragmented market, and risks including regulatory changes and competition. Analysts hold a cautious "Hold" rating with potential upside, making it a defensive play for long-term investors.
Daytona Street Capital LLC Invests $2.69 Million in CVS Health Corporation $CVS
Daytona Street Capital LLC has acquired a new position of 33,888 shares in CVS Health Corporation, valued at approximately $2.69 million, making it their 16th largest holding. This investment comes as CVS reported strong Q4 results, exceeding EPS and revenue estimates, and announced a quarterly dividend of $0.665. Analysts maintain a "Moderate Buy" rating for CVS with an average target price of $94.95.
Fulton Breakefield Broenniman LLC Has $14.87 Million Stock Position in UnitedHealth Group Incorporated $UNH
Fulton Breakefield Broenniman LLC reduced its stake in UnitedHealth Group (UNH) by 8.3% in Q4, now holding 45,041 shares valued at $14.87 million. The healthcare conglomerate is experiencing positive sentiment due to a larger-than-expected Medicare Advantage payment increase for 2027, boosting its revenue outlook. Analysts maintain a "Moderate Buy" rating with a target price of $363.38, while the company anticipates Q1 earnings on April 21st.
Country Trust Bank Increases Holdings in UnitedHealth Group Incorporated $UNH
Country Trust Bank increased its stake in UnitedHealth Group (UNH) by 14.7% in Q4, acquiring an additional 18,484 shares, making UNH its 28th largest position valued at $47.5 million. The company reported solid Q4 earnings, slightly beating expectations, and provided positive FY2026 EPS guidance. Upcoming Q1 results on April 21st and a favorable CMS decision for Medicare Advantage payments are key near-term catalysts for UNH amidst recent stock weakness.
Insurance stocks jump on Medicare Advantage rate boost: Humana, UnitedHealth, lead gains (UNH:NYSE)
Insurance stocks, including Humana and UnitedHealth, saw increases after the Centers for Medicare & Medicaid Services (CMS) announced a 2.48% boost in average Medicare Advantage payments for 2027, totaling over $13 billion. This positive news led to gains for major insurance companies in after-hours trading.
Humana Releases 2025 Impact Report on Affordable Care
Humana, a major healthcare provider, has released its 2025 Impact Report, detailing its efforts to make healthcare more affordable and accessible. The report highlights the company's commitment to reducing administrative burdens, expanding telehealth options, and implementing value-based care models. Humana plans to continue these initiatives, focusing on digital tools and value-based care to improve the patient experience and provide equitable access to quality care.
New Medicare Payment Rate Released. Why UnitedHealth Stock Is Popping.
The federal government has announced a 2.48% average increase in Medicare payments to insurers for next year, a significant financial update for major health insurance companies. This news has led to a rise in UnitedHealth's stock. Medicare Advantage is a crucial business segment for these insurers, covering 35 million beneficiaries.
UnitedHealth, Humana, Health Insurers Jump On Higher Medicare Advantage Payments
UnitedHealth Group, Humana, and CVS Health saw their stock prices rise following an announcement by the Trump administration regarding higher-than-expected Medicare Advantage payment rates for 2027. The Centers for Medicare and Medicaid Services stated that rates would increase by 2.48%, totaling $13 billion, moving significantly upward from the proposed 0.09% gain announced in January. This positive adjustment in payment rates led to a jump in shares for these health insurers.
CVS, UnitedHealth, Humana, Elevance Shares Surge: Here's Why
Shares of several major health insurers, including CVS, UnitedHealth, Humana, and Elevance, saw significant after-hours gains on Monday. This surge followed the Centers for Medicare and Medicaid Services (CMS) finalizing payment policies for 2027, projecting a net average increase of 2.48% for Medicare Advantage (MA) and Part D plans. The CMS stated that these updates aim to keep coverage affordable and ensure value for patients.
Medicare Finalizes 2.48% Rate Hike for Private Insurers in 2027
The US Medicare program has finalized a 2.48% rate increase for private insurers in 2027, marking a significant improvement over the initial rates proposed earlier by the agency. This decision from the Centers for Medicare and Medicaid Services is expected to influence how over half a trillion dollars are distributed among private health plans offered by major companies like UnitedHealth Group, Humana Inc., and CVS Health Corp. The news led to a climb in stock for companies like Humana and CVS.
Wolfe Adjusts Price Target on Humana to $250 From $325, Maintains Outperform Rating
Wolfe has adjusted its price target for Humana (HUM) shares, lowering it to $250 from the previous $325. Despite this reduction, the firm has chosen to maintain an Outperform rating on the healthcare company's stock. This decision comes amidst other recent adjustments in analyst price targets for Humana.
Humana Inc price extends cautious gains - Forecast today - 06-04-2026
Humana Inc. (HUM) stock price shows cautious gains, benefiting from positive Stochastic indicator signals after easing some overbought conditions. However, the indicator remains at extreme overbought levels, and trading below its 50-day SMA suggests a potential decline. The forecast indicates bearish movement, with an expected drop to the $163.60 support level if resistance at $192.00 holds.
Humana says 1.6 million lives were touched by 2025 community efforts
Humana released its 2025 Impact Report, highlighting progress in making healthcare simpler, more affordable, and more connected. The report details advancements in supporting individuals, strengthening communities, and enhancing environmental stewardship, including reaching 1.6 million lives through community efforts and serving nearly 8 million Medicare Advantage members. Humana's CEO, Jim Rechtin, emphasized the company's commitment to customer-centric care and community building.
UnitedHealth Group Incorporated Trade Ideas — LS:869561
This article compiles various trading ideas and analyses for UnitedHealth Group (UNH), highlighting both technical and fundamental perspectives. Several traders suggest bullish long positions based on technical indicators like bullish reversal patterns, demand zones, and moving average crossovers, while others emphasize UNH's strong fundamentals as a diversified healthcare giant. The article also includes an AI analysis of insider buying patterns for UNH and other companies, and offers different trade plans with entry, stop loss, and take profit targets.
Perpetual Ltd Invests $19.94 Million in Humana Inc. $HUM
Perpetual Ltd recently purchased 77,843 shares of Humana Inc. for approximately $19.94 million, representing about 0.06% ownership in the company. This investment comes as Humana reported slightly better-than-expected quarterly earnings and declared a quarterly dividend of $0.885, despite receiving several analyst downgrades. The stock currently holds a "Hold" consensus rating with an average target price of $225.48.
Aberdeen Group plc Acquires 43,442 Shares of Humana Inc. $HUM
Aberdeen Group plc significantly increased its stake in Humana Inc. by 18.1% in the fourth quarter, purchasing 43,442 shares and bringing its total holdings to 283,778 shares valued at $72.68 million. This acquisition makes Aberdeen Group plc own 0.24% of Humana. The company's recent financial results showed an EPS of ($3.96), surpassing estimates, with revenue rising 11.3% to $32.64 billion, and analysts maintaining a "Hold" rating with an average target price of $225.48.
Humana (HUM) executive boosts holdings through equity vesting and tax withholding
Humana Inc.'s President, CenterWell, Sanjay K. Shetty, acquired 887 common shares through performance-related equity awards on April 1, 2026. Concurrently, 401 shares were withheld to cover tax liabilities, resulting in a net increase of 486 common shares. After these transactions, Shetty directly owns 12,143 Humana common shares, including restricted stock units and performance stock units, and retains stock options for an additional 10,536 underlying shares.
CFOs On the Move: Week ending April 3
This article details recent CFO appointments and departures across various companies. Key moves include Wadih Khayat to Driscoll's from Coca-Cola, Sean McSherry's internal promotion at Indeed, and Amie Thuener joining Broadcom from Alphabet. The article also covers CFO changes at Avantor, Pentera, Zaxby's, Bloom Energy, TouchTunes, Packsize, and Clover Health, highlighting the dynamic landscape of finance leadership.
Humana, Inc. Experiences Valuation Adjustment Amidst Competitive Healthcare Market Dynamics
Humana, Inc. has seen a valuation adjustment, with its stock currently priced at $176.95. The company's stock return has declined by 33.16% over the past year, contrasting with the S&P 500's 16.73% increase. Despite this, Humana maintains a premium market positioning relative to peers like Centene Corp., indicating competitive dynamics within the healthcare services sector.
Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives
Plus Therapeutics Inc. announced that its CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay has secured coverage with Highmark, effective April 1, 2026. This agreement expands CNSide's total covered lives from approximately 67 million to 75 million, reinforcing the company's objective of 150 million covered lives by 2026. The CNSide assay provides earlier and more accurate detection of leptomeningeal metastases, with demonstrated clinical and economic value.
Molina Healthcare, Inc. (MOH) stock price, news, quote and history
This page provides comprehensive information on Molina Healthcare, Inc. (MOH) stock, including its current price, historical data, financial performance, and analyst ratings. The stock closed at $134.03, down 3.44%, with recent news highlighting its Q4 earnings, a 55% one-year share price fall, and a new position by billionaire Seth Klarman. The company operates in healthcare plans, primarily serving low-income families through Medicaid, Medicare, and state insurance marketplaces.
Humana (NYSE: HUM) president updates phantom units, options and RSUs
Humana Inc.'s President of Insurance, George Renaudin II, reported routine compensation-related activities including an annual contribution of 25 Phantom Stock Units. His holdings now include 199 indirect Phantom Stock Units, 16,075 direct common shares, 542 indirect common shares, stock options for 4,162 shares expiring in 2030, options for 6,966 shares expiring in 2031, and 9,059 restricted stock units. This Form 4 filing details these compensation structures and does not indicate open-market buying or selling.
Humana (NYSE: HUM) director granted RSUs and reports share holdings
Humana Inc. director Kurt J. Hilzinger was granted 536 Restricted Stock Units (RSUs) as compensation, valued at $170.6605 per unit. These RSUs, along with other deferred stock units and dividend-equivalent units, will convert to Humana common shares upon his departure from the board. Hilzinger also directly holds 19,448 Humana common shares.
Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives
Plus Therapeutics, Inc., through its subsidiary CNSide Diagnostics, LLC, has secured a new payer coverage agreement with Highmark for its CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay. This agreement expands CNSide's total covered lives from approximately 67 million to 75 million, significantly reducing reimbursement barriers for physicians. The CNSide® CSF Assay Platform offers earlier and more accurate detection of leptomeningeal metastases compared to conventional methods, demonstrating high sensitivity and specificity in clinical use.
Cigna posts Q1 results by 6:30 a.m. ET, holds investor call April 30
The Cigna Group (NYSE: CI) announced it will release its first quarter 2026 financial results on April 30, 2026, by 6:30 a.m. ET. Management will host a conference call to discuss these results at 8:30 a.m. ET, with a live webcast and replay available. This announcement continues the company's established practice of pre-announcing earnings logistics, with historical data showing an average -5.52% stock move following previous earnings-tagged events, despite often positive fundamentals.
Humana (HUM) Valuation Check As Shares Face Ongoing Medicare Advantage Regulatory Pressure
Humana (HUM) shares have faced a significant decline over the past year, trading at $176.95, which is below its fair value estimate of $212.87. This undervaluation is largely due to increasing regulatory pressure on Medicare Advantage, a key growth driver for the company. The valuation is dependent on how well Medicare Advantage profitability holds up against new rules and the potential for audit repayments.
Cancer screening rates dip in US as cost concerns deter access
A new survey by the Prevent Cancer Foundation indicates that nearly three-quarters of U.S. adults are behind on routine cancer screenings, a 4% increase from the previous year. Financial strain, particularly concerns about unexpected costs and potential follow-up tests, is a major contributing factor, even though initial screenings are often covered as preventive care. Additionally, a lack of patient education, logistical barriers, and flagging trust in the healthcare industry are also hindering screening rates.
How Hospices Can Work with ‘Payviders’
Hospices need to understand and align with "payviders" – insurance companies that also own healthcare provider businesses – as this model grows. Companies like Humana, UnitedHealth Group, and SCAN Group are examples of payviders, which aim to reduce healthcare fragmentation and improve care coordination. Hospices should prepare for increased financial alignment and accountability for outcomes when partnering with these entities, emphasizing close coordination, especially with primary care physicians.
Leerink sees UnitedHealth stock facing largest RADV audit exposure
Leerink's report indicates that the Centers for Medicare & Medicaid Services (CMS) is significantly expanding its 2020 Risk Adjustment Data Validation (RADV) audits, reviewing 470 Medicare Advantage contracts compared to 58 in 2018. UnitedHealth Group (NYSE:UNH) faces the most substantial exposure, with 60 contracts covering 92% of its 2020 Medicare Advantage membership under review. All publicly traded Medicare Advantage plans are included in these expanded audits, which will begin processing in April 2025.
Allspring Global Investments Reduces Stake in Humana
Allspring Global Investments Holdings LLC significantly reduced its stake in Humana Inc. (NYSE:HUM) by 40.9% during Q4 2025, selling 391,300 shares. This move leaves the firm with 565,443 shares, representing 0.47% of Humana's outstanding shares. The reduction could indicate a shift in investor sentiment or be part of Allspring's portfolio rebalancing efforts, warranting close observation by other investors.
Vivos Therapeutics’ Supported Practices Achieve In-Network Status in Nevada
Vivos Therapeutics announced that physician-owned practices it supports in Nevada have achieved in-network status with major commercial insurers and Medicare, significantly expanding patient access to its obstructive sleep apnea treatments. This development is expected to boost medical referrals and increase revenue in the Las Vegas market. Concurrently, Vivos is implementing cost-reduction initiatives in its legacy dental distribution model, anticipating $4 million in annual savings to help the company achieve cash flow positivity in fiscal year 2026.
Progyny (NASDAQ: PGNY) schedules virtual 2026 meeting; board, audit ratification on ballot
Progyny (NASDAQ: PGNY) has scheduled its 2026 virtual annual meeting for May 21, 2026, with a record date of March 27, 2026, and 78.3 million shares outstanding. Stockholders will vote on the election of three Class I directors, ratification of Ernst & Young LLP as the independent auditor, an advisory vote on executive compensation, and two amendments to the Certificate of Incorporation to eliminate certain supermajority voting requirements. The proposed amendments aim to streamline governance by changing the voting threshold for several corporate actions from two-thirds to a simple majority of outstanding shares.
Humana Inc. stock outperforms competitors on strong trading day
Humana Inc. (HUM) shares rose 4.45% to $173.39 on Tuesday, outperforming competitors and the broader market. This gain snapped a two-day losing streak for the stock, as the S&P 500 and Dow Jones Industrial Average also saw significant increases.
Cyber Threats - CareCloud reports data breach after cyberattack disrupts EHR system
CareCloud Inc., a New Jersey-based healthcare IT company, has reported a data breach following a cyberattack on March 16. The attack disrupted one of its electronic health record systems, leading to the exposure of sensitive patient data.
Elevance fills slew of mid-level leadership positions
Elevance has announced several mid-level executive appointments, particularly within its health benefits division and its Carelon health services division. These leadership changes aim to improve execution and support growth, especially in Carelon, which has been a strong performer amidst struggling profits in the core health benefits division. New roles include Carelon's first chief growth and strategy officer and new presidents and CFOs across both segments.
New Carelon chiefs will oversee services for 90 million consumers
Elevance Health has announced leadership appointments across its Health Benefits and Carelon organizations to strengthen execution and drive growth. These changes are intended to better align capabilities, accelerate decision-making, and improve enterprise efficiency for Carelon, which serves over 90 million consumers. The new appointments include leaders for Government Business, Carelon Health, Carelon Insights, and Chief Growth and Strategy Officer and CFO roles for Carelon and Health Benefits.
Humana Inc. (NYSE:HUM) Receives Average Recommendation of "Hold" from Brokerages
Humana Inc. (NYSE:HUM) has an average "Hold" rating from 26 brokerages, with price targets ranging from $158 to $344. The company recently reported better-than-expected Q4 earnings and revenue, even as it provided FY 2026 guidance. Institutional investors hold a significant portion of the stock, and an insider recently increased their stake.
Humana Inc (HUM) Shares Down 3.45% on Mar 30
Humana Inc (HUM) shares dropped 3.45% on March 30, closing at $169.09, significantly below its 52-week high. Wall Street analysts forecast an average target price of $217.94, suggesting a 28.89% upside, while GuruFocus estimates a GF Value of $506.32, implying a 199.44% upside, with a consensus "Hold" rating from brokerage firms.
Humana Inc. to Release First Quarter 2026 Results on April 29, 2026
Humana Inc. (NYSE: HUM) announced it will release its first-quarter 2026 financial results, along with prepared management remarks, at 6:00 a.m. Eastern time on April 29, 2026. The company will also host a live question-and-answer session at 8:00 a.m. Eastern time that morning to discuss the results and earnings guidance for 2026. A webcast of the earnings call and the news release will be available on Humana's Investor Relations page.
Humana Inc. to Release First Quarter 2026 Results on April 29, 2026
Humana Inc. (NYSE: HUM) announced it will release its first-quarter 2026 financial results, including prepared management remarks, at 6:00 a.m. Eastern time on April 29, 2026. The company will also host a live question-and-answer session at 8:00 a.m. EDT to discuss the results and earnings guidance for the year, accessible via webcast on their Investor Relations page. Financial measures not in accordance with GAAP will be reconciled in the earnings news release, available on their website.
Former Humana executive takes over Sun Life dental unit serving 32M
Sun Life U.S. has appointed Tony Mollica, a former Humana executive, as the new president of its Dental business, which includes DentaQuest, effective March 30, 2026. Mollica will be responsible for the strategic direction, growth, and managed care strategies for the unit, which currently serves approximately 32 million people nationwide across Medicaid, Commercial, and Medicare Advantage segments. His appointment aims to enhance access to quality oral healthcare and drive client and member satisfaction.
Humana, Caught up in the Metastasizing Medicare Overbilling Scandal, Enters Our Imploded Stocks
Humana's stock has plunged 71% from its November 2022 high, entering the "Imploded Stocks" list due to a government crackdown on Medicare Advantage overbilling. The company faces allegations of finding or exaggerating health problems to claim higher payments, and a recent lawsuit regarding kickbacks to steer beneficiaries to their plans. This highlights how corporate profits driven by government overbilling can lead to significant financial repercussions for companies when regulatory scrutiny intensifies.
Humana Inc. stock underperforms Monday when compared to competitors
Humana Inc. (HUM) shares fell 1.83% to $166.00 on Monday, marking its second consecutive day of losses. This underperformance occurred during a mixed trading session where the Dow Jones Industrial Average rose, but the S&P 500 Index declined. The article highlights the stock's performance relative to its competitors and broader market indices.
Sun Life U.S. names Tony Mollica as new dental business leader
Sun Life U.S. has appointed Tony Mollica as the new president for its Dental business, including DentaQuest, effective March 30, 2026. Mollica, formerly a Humana executive, will focus on strategic direction, growth across various dental segments, and enhancing relationships with stakeholders. He succeeds David Healy, who became president of Sun Life U.S., and will bring his extensive health plan leadership experience to improve oral healthcare access and quality.
Enhabit (EHAB) deal: $13.80 cash takeover backed by Kinderhook ($688M equity)
Enhabit, Inc. is being acquired by Anchor Parent, LLC, an affiliate of Kinderhook Industries, for $13.80 per share in cash, representing a 33.8% premium to its 60-day volume-weighted average price through February 20, 2026. Kinderhook-affiliated funds are committing $688 million in equity to fund the $690.4 million transaction, which is unanimously recommended by Enhabit's Board of Directors. The deal will result in Enhabit becoming a private company, delisting its stock from the NYSE, and ceasing SEC filings.
